Response: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)

Lignende værker

• Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)
  af: Rhee, Sang Youl
  Udgivet: (2020)
• Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
  af: Jang, Han Na, et al.
  Udgivet: (2019)
• Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
  af: Wang, Fei, et al.
  Udgivet: (2012)
• Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
  af: Cho, Kyu Yong, et al.
  Udgivet: (2020)
• Tresiba (Insulin Degludec Injection) and Ryzodeg 70/30 (Insulin Degludec and Insulin Aspart Injection): Two New Insulin Analogs for Glycemic Control in Diabetes Mellitus
  af: Raedler, Lisa A.
  Udgivet: (2016)